NovoCure Limited - Ordinary Shares (NVCR)

This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

NovoCure (NVCR) Q1 2026 Earnings Transcript

NovoCure (NVCR) Q4 2025 Earnings Call Transcript

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

H.C. Wainwright raised the firm's price target on Novocure to $47 from $39 and kept a ‘Buy’ rating on the shares after the company announced FDA approval of Optune Pax.

The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of February 12, 2026. Introduction NovoCure Limited (NASDAQ: NVCR) stands as a unique outlier in the oncology landscape. Unlike the traditional pharmaceutical giants that dominate the space with [...]

The stock is on track to record its best day since December 2024 if the overnight gains hold.

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NovoCure (NVCR) Q3 2024 Earnings Call Transcript

Novocure (NVCR) Q2 2025 Earnings Call Transcript

NovoCure (NVCR) Q3 2025 Earnings Call Transcript

If you have decades of investing runway left, consider these two top healthcare stocks.